Gastrointestinal Stromal Tumor (GIST) Market Research Report-Size, Share, Growth, and Trend Analysis | Forecast (2022 - 2032)
The Gastrointestinal Stromal Tumor (GIST) Market is a specialized segment within the oncology therapeutics field, addressing the treatment and management of one of the most common forms of sarcomas affecting the gastrointestinal tract. Characterized by mutations in the KIT or PDGFRA genes, GIST poses unique challenges and opportunities for targeted and precision medicine approaches. This market encompasses therapies ranging from tyrosine kinase inhibitors (TKIs) to innovative emerging treatments aimed at improving survival outcomes and quality of life for patients.
Disruptive Impact and Opportunities:
The GIST market is experiencing a wave of disruption through advancements in targeted therapies and novel mechanisms of action. Emerging drugs such as Famitinib, Nilotinib, THE-630, DS 6157, and Crenolanib hold transformative potential by addressing unmet needs in treatment resistance and advanced-stage disease management. Marketed therapies like Gleevec/Glivec (Imatinib Mesylate) and Qinlock (Ripretinib) have set benchmarks in efficacy, but new entrants are poised to reshape therapeutic landscapes with enhanced efficacy and safety profiles.
Emerging Drugs:
- Famitinib
- Nilotinib
- THE-630
- DS 6157
- Crenolanib
Marketed Drugs:
- Gleevec/Glivec (Imatinib Mesylate)
- Qinlock (Ripretinib)
Key Companies:
- Arog Pharmaceuticals
- Taiho Pharmaceutical
- Turning Point Therapeutics, Inc.
- Cogent Biosciences, Inc.
- Plexxikon Inc.
- Theseus Pharmaceuticals
- Exelixis, Inc.
- Ipsen
- Bristol-Myers Squibb
- Takeda
Market Segmentation:
By Type
· Targeted Therapies
- Tyrosine Kinase Inhibitors (TKIs)
- First-line TKIs
- Second-line TKIs
- Third-line TKIs
- Immune Checkpoint Inhibitors
· Chemotherapy
· Supportive Care Therapies
· Others
By Administration Type
- Oral
- Intravenous
- Others
What’s in It for You?
- Identify emerging opportunities in the GIST market with a focus on disruptive innovation and unmet needs.
- Gain actionable insights into the competitive landscape and evolving treatment paradigms.
- Evaluate the potential of late-stage pipeline drugs for strategic portfolio expansion.
- Leverage market dynamics to develop robust market entry or expansion strategies.
- Understand the evolving preferences of oncologists and healthcare providers to align product positioning effectively.
Gastrointestinal Stromal Tumor Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)
1. Gastrointestinal Stromal Tumor Market - Executive Summary
1.1 Introduction
1.2 Objectives
1.3 Key Findings
1.3.1 Market Size 2025 & 2030: By Key Country (10MM)
1.3.2 Global Market Size 2025 & 2030: By Key Segment
1.3.3 Key Investments & Startup Analysis
1.4 Research Methodology
2. Understanding the Disease
2.1 Disease Overview
2.2 Classification
2.3 Signs and Symptoms
2.4 Risk Factors
2.5 Causes
2.6 Disease Biology & Digital Innovations
2.7 Stages & Staging System
2.8 Diagnostic Algorithm
2.9 Current Treatment Practices & Algorithm
2.10 Current Standard of Care and Treatment Gaps
2.11 Patient Demographics and Treatment Pathways
3. Guidelines
4. Unmet Needs
5. Epidemiology and Patient Population
5.1 Epidemiology Key Findings
5.2 Assumptions and Rationale: 10MM
5.3 Epidemiology Scenario: 10MM
5.4 U.S. Epidemiology Scenario
5.5 EU-5 Epidemiology
5.5.1 U.K. Epidemiology Scenario
5.5.2 Germany Epidemiology Scenario
5.5.3 France Epidemiology Scenario
5.5.4 Italy Epidemiology Scenario
5.5.5 Spain Epidemiology Scenario
5.6 Japan Epidemiology Scenario
5.7 China Epidemiology Scenario
5.8 Australia Epidemiology Scenario
5.9 India Epidemiology Scenario
6. Real-world Data & Real-world Evidence
7. Drug Development Landscape
7.1 Existing Key Drug Candidate Profiles/ Marketed Therapies
7.1.1 Gleevec/Glivec (Imatinib Mesylate)
7.1.1.1 Product Description
7.1.1.2 Regulatory Milestones
7.1.1.3 Other Developmental Activities
7.1.1.4 Pivotal Clinical Trials
7.1.1.5 Ongoing Current Pipeline Activity
7.1.2 Qinlock (Ripretinib)
7.1.2.1 Product Description
7.1.2.2 Regulatory Milestones
7.1.2.3 Other Developmental Activities
7.1.2.4 Pivotal Clinical Trials
7.1.2.5 Ongoing Current Pipeline Activity
7.2 Competitive Analysis and Differentiation
7.3 Overview of Similar/Competing Drugs in Clinical Trials
7.4 Future Trends and Emerging Drugs
7.4.1 Famitinib
7.4.1.1 Product Description
7.4.1.2 Clinical Development
7.4.1.3 Safety and Efficacy
7.4.2 Nilotinib
7.4.2.1 Product Description
7.4.2.2 Clinical Development
7.4.2.3 Safety and Efficacy
7.4.3 THE-630
7.4.3.1 Product Description
7.4.3.2 Clinical Development
7.4.3.3 Safety and Efficacy
7.4.4 Crenolanib
7.4.4.1 Product Description
7.4.4.2 Clinical Development
7.4.4.3 Safety and Efficacy
8. Regulatory Strategy and Potential Challenges
8.1 Regulatory Pathways in Key Markets
8.2 Anticipated Regulatory Hurdles and Mitigation Strategies
8.3 Case Studies in Oncology Drug Regulation
8.4 Impact of Potential Changes to Regulatory Framework
9. Commercial Landscape
9.1 Market Size & Growth Rates
9.2 Key Approvals & Anticipated Loss of Exclusivity
9.3 PESTLE & Porter’s Five Forces Analysis
9.4 Market Shares, Positioning/Ranking
9.5 Market Drivers
9.6 Identification of Threats
9.7 Digital Evolution in Commercialization
10. Market Segmentation
10.1 Market by Route of Administration
10.1.1 Oral
10.1.2 Parenteral
10.1.3 Others
10.2 Market by Therapy Type
10.2.1 Chemotherapy
10.2.2 Radiotherapy
10.2.3 Targeted therapy
11. Pricing, Reimbursement, and Access
11.1 Competitive Pricing Analysis
11.2 Reimbursement Landscape and Challenges
11.3 Strategies for Market Access and Equity
11.4 Patient Spending/Expenditure Analysis
12. Future Trends, Disruptions, and Opportunities
12.1 Analysis of Emerging Trends
12.2 Technological Impact
12.3 Impact of Potential Market Disruptors
12.4 Opportunities for Future Development and Expansion
12.5 Considerations for Investment Opportunities
13. Global Market Dynamics
13.1 Regional Regulatory Disparities
13.2 Cross-Border Partnership Strategies
13.3 Global Supply Chain Dynamics
13.4 Case Studies: Success and Failure in Global Markets
13.5 Strategies for Global Expansion and Localization
14. Company Profiles
14.1 Arog Pharmaceuticals
14.2 Taiho Pharmaceutical
14.3 Turning Point Therapeutics, Inc.
14.4 Cogent Biosciences, Inc.
14.5 Plexxikon Inc.
14.6 Theseus Pharmaceuticals
14.7 Exelixis, Inc.
14.8 Ipsen
14.9 Bristol-Myers Squibb
14.10 Takeda
Download Sample
Choose License Type
2500
4250
5250
6900
